Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer

Anna Forsythe,1 David Chandiwana,2 Janina Barth,3 Marroon Thabane,4 Johan Baeck,2 Gabriel Tremblay1 1Purple Squirrel Economics, New York, NY, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 3Novartis Pharma GmbH, Nuremberg, Germany; 4Novartis Pharmaceuticals Incorporated, Dorval, QC, C...

Full description

Bibliographic Details
Main Authors: Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Tremblay G
Format: Article
Language:English
Published: Dove Medical Press 2018-05-01
Series:Breast Cancer : Targets and Therapy
Subjects:
Breast cancer
overall survival
progression-free survival
time to progression
correlation analysis
surrogate endpoint
Online Access:https://www.dovepress.com/progression-free-survivaltime-to-progression-as-a-potential-surrogate--peer-reviewed-article-BCTT

Internet

https://www.dovepress.com/progression-free-survivaltime-to-progression-as-a-potential-surrogate--peer-reviewed-article-BCTT

Similar Items